Solid lipid nanoparticles as drug delivery systems for MicroRNA by Tucak, Amina et al.
III. Symposium of Young Researchers on Pharmaceutical 
Technology, Biotechnology and Regulatory Science 






Solid Lipid Nanoparticles as Drug Delivery Systems for 
MicroRNA 
Amina Tucak1, Merima Sirbubalo1, Edina Vranić1, Andreas 
Zimmer2 
1Department of Pharmaceutical Technology, Faculty of Pharmacy, University of 
Sarajevo, Sarajevo, Bosnia and Herzegovina 
2Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmaceutical Sciences, University 
of Graz, Graz, Austria 
 
MicroRNA-based medicines have drawn attention as a promising tool for the treatment of 
various diseases. Due to the poor biomembrane permeation, cellular uptake, and enzymatic 
instability of naked microRNA, the clinical success of gene therapy is mostly dependent on 
formulating efficient and safe transfection vectors [1]. Therefore, we aimed to develop 
cationic solid lipid nanoparticles (SLN) for gene therapy purposes.  
SLN containing 0.15% of stearylamine, 4.85% of Precirol ATO 5 (solid lipid), 1% of Tween 80, 
and 1% of Poloxamer 188, as non-ionic surfactants, were produced using a high-pressure 
homogenization process (800 bar and three cycles). microRNA 27-a was further complexed 
with SLN in the following SLN/microRNA ratios: 1:5, 1:2.5, 1:1, 2.5:1, 5:1, 10:1, 25:1 and 
characterized using dynamic light scattering, electrophoretic light scattering, and gel 
retardation assay. 
The SLN had a mean diameter of 112 ± 0.5 nm (PDI of 0.202 ± 0.011) and a zeta potential (ZP) 
value of +30.6 ± 1.25 mV. Complexation of SLNs with microRNA decreased a particle size from 
244.8 ± 2.7 to 120.4 ± 0.4 nm with an increasing weight ratio of SLNs, while the biggest particle 
size was observed in 1:1 ratio (1146 ± 110.2 nm) due to low ZP values (3.45 ± 0.2 mV). Further, 
ZP increased from -14.3 ± 0.4 mV to + 39.7 ± 0.5 mV. Both ELS data and gel retardation assay 
results revealed that complete complexation could be attained above the weight ratio of 5:1. 
Our investigations suggest that SLN poses a high potential to be non-viral gene carriers in 
miRNA replacement therapy. 
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